

Leading the
REVOLUTION

2009 AACP Annual Meeting and Seminars
July 18–22 • Boston
Westin Boston Waterfront Hotel

American Association of
Colleges of Pharmacy **AACP**
Discover • Learn • Care! Improve Health

**Pharmacogenetics and the PharmD
Curriculum: Examples from the UIC
College of Pharmacy**

Jeffrey R. Bishop, Pharm.D., B.C.P.P.
Assistant Professor
UIC Dept of Pharmacy Practice
UIC Pharmacogenomics Laboratory

UIC COLLEGE OF
UNIVERSITY OF ILLINOIS PHARMACY
AT CHICAGO

UIC PHARMACOGENOMICS
LABORATORY

Goals and Objectives

- To review the integration of pharmacogenetics/genomics (PGx) in UIC PharmD curriculum
- To discuss the type of PGx information included in PharmD courses
 - Required courses/lecture based
 - Electives
 - Lab experiences
- Barriers to integration
 - Challenges
 - Opportunities

Integrating Pharmacogenomics into Patient Care



“...pharmacogenetics promises to target treatment to a patient’s genetic profile...”
 Newsweek June 25, 2001

Clinical Applications

- FDA approved drugs with PGx info on labeling
 - N=7 with “recommended” action in the label
 - N=69 labels mentioning human genomic biomarkers
 - N=52 labels mentioning microbial genomic biomarkers




Figure 2. Number of drugs that were approved with pharmacogenomic information in their drug labels during each 10-year period from 1945–2005. During the 60 years covered by this analysis, 121 drugs were approved that have genomic biomarker information in current product labeling.

Flockhart DA et al. *Clin Pharmacol Ther* 2009

genelex | Health & DNA
Accredited DNA Testing Pioneers Since 1987

Home | Paternity | Drug Safety | Ancestry | Clinical Trials | Predictive Genetics | DNA Learning Center | About Genelex | Store

Home » Drug Safety » DNA Drug Reaction Testing

DNA Drug Reaction Testing

Do not alter the dosage amount or schedule of any drug you are taking without first consulting your medical provider or pharmacist.

Research shows that of all the clinical factors such as age, sex, weight, general health and liver function that alter a patient's response to drugs, genetic factors are the most important. This information becomes even more crucial when you consider the fact that adverse reactions to prescription drugs are killing about 106,000 Americans each year—roughly three times as many as are killed by automobiles. This makes prescription drugs the fourth leading killer in the U.S., after heart disease, cancer, and stroke.

We currently offer CYP2D6, CYP2C9, CYP2C19, NAT2 and CYP1A2 screens that can help your physician or pharmacist predict your particular response to many prescription, OTC (over-the-counter) and herbal medicines including those used to treat depression, anxiety, seizures and psychosis; heart disease, cancer, diabetes, and pain. These include such important medications as Coumadin (warfarin), Prozac, Zoloft, Paxil, Effexor, hydrocodone, amitriptyline, Claritin, cyclobenzaprine, Haldol, metoprolol, Rhythmol, Tagamet, famoxifen, Valium, carisoprodol, diazepam, Dilantin, Preemant, and Preevac (and the over-the-counter drugs, Allegra, Dytuss and Tusstat). [Click here to view a more complete list of drugs processed through these pathways.](#)

Approximately half of all Americans have genetic defects that affect how they process these drugs. There are four different types of metabolizers, and we all fall into one of these categories for the variable pathways in Cytochrome P450 (this Cytochrome is responsible for creating the enzymes that process chemicals of all kinds through our bodies.) The easiest way to understand this is to picture a two lane highway.

- If you are the first type which is the norm, you would be a Normal Metabolizer. Both lanes of the highway are open and moving. Medications prescribed in normal doses will be metabolized by your body.
- If you are the second type, you would be an INTERMEDIATE metabolizer. This means that one lane of that highway is open and moving and the other lane is not, causing you to metabolize the medications more slowly. In this case you will need a lower dosage, and there is a chance of medications building up in your system causing adverse effects. It is especially important to monitor medications if you are in this category.
- Intermediate metabolizers through the 2C9 pathway, for instance, have an increased risk of bleeding incidences when taking the common blood thinner Coumadin or warfarin. For this reason, a recent article in the *Journal of the*

Genelex will be happy to mail information to you or to your healthcare provider on your behalf, simply complete the [request form](#).

Questions? Call us at **1-800-523-3080** to speak with a DNA Testing Consultant

Request a Call | Live Chat

Order your test today! Go to our Online Store

Healthcare Professionals

Pharmacogenetics testing can help guide clinical medication management. [Click Here to Learn More.](#)

Select a Drug or Health Condition

- Clopidogrel
- Warfarin
- Tamoxifen
- Fluorouracil
- Irinotecan
- Sheltona
- Other Medications
- Depression
- Heart Disease
- Cancer
- Pain

What our clients say...

"I just wanted to call and tell you that my physician switched my medications based on my test results, and I cannot describe how much better I feel. You have made a believer out of me, my family, and my physician. I hope this testing becomes routine before anyone is placed on long term medication."
-PV, Elko, CO

GeneMedRx
Protect Yourself. Protect Your Family. Check for drug interactions.
Adverse Drug Reactions are the 4th leading cause of death in the U.S. GeneMedRx drug interaction software can help reduce the risk.
[Try it FREE!](#)

DNA Today

THE CYP450 GENES
Drug Metabolism and Ancestry

The likelihood that someone is a Poor Metabolizer (PM) or an Ultra Metabolizer (UM) depends, to some degree, on that person's genetic heritage. It is important to realize that the distribution of these gene variants may differ significantly between groups that people might otherwise consider the same ethnicity. For example, Ethiopians have very high rates of 2D6 Ultra Metabolizers, while South Africans have very high rates of 2D6 Poor Metabolizers.

Table: Drug Metabolism Variation by Ethnicity
 Drug Metabolism and Ethnicity

Drug Metabolism Variation by Ethnicity

The table below lists common drug metabolism gene variants and their frequencies in major ethnic groups.

Gene and Variant	Caucasians	African-Americans	Asians
CYP2D6*3	2%	0	0
CYP2D6*4	12-21%	2%	1%
CYP2D6*5	2-7%	4%	4%
CYP2D6*10	1-2%	4%	51%
CYP2D6*17	0	34%	0%
CYP2D6*2XN	1-5%	2%	0-2%
CYP2C9*2	8-14%	1%	0%
CYP2C9*3	4-14%	1-2%	2-3%
CYP2C9*5	-	1.7%	-
CYP2C9*6	-	0.4%	-
CYP2C19*2	15%	17%	30%
CYP2C19*3	0-04%	0-40%	5%

Adapted from Blue Cross Blue Shield Special report

Drug Metabolism and Ethnicity

What we tend to think of as ethnicity is not always reflected in genetic differences. In many parts of the world, people have so thoroughly mixed their gene pools over time that it is often impossible to predict whether or not a person identified with a particular ethnicity carries a gene variant that is common to that ethnicity.

Provider Education is Needed

- Pharmacy
 - ACPE requires PGx education for PharmD students
 - No specific hours
- Medicals Schools
 - Average 1-2hrs (range 1-4hrs) (Higgs 2009 – UK study)

November/December 2005 - Vol. 7 - No. 9

Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: A global problem

Morichek J.H. Burns, MD¹, Lidewij Hemmenas, PhD^{2,3}, and Leo P. van Ranc, MD, PhD³

The Pharmacogenomics Journal (2005) 5: 201-205
 © 2005, Year Publishing Group of International Pharmaceutical Education
 www.pjg.com

CONSENSUS ARTICLE

Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education

122 **Opinion** TRENDS in Pharmacological Sciences Vol.29 No.3 March 2008

Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine

David Gurwitz¹, Abraham Weizman² and Moshe Rehavi³

¹Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
³Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

UIC College of Pharmacy

- Professional Students: 650
- Graduate students: 138
- Residents/fellows: 29
- Faculty: 90
- Pharmacy Programs: 6 (5 doctoral)

UIC College of Pharmacy

- PGx in the PharmD curriculum
 - Genetic basis for disease and drug action
 - Genetic basis for alteration of drug metabolism
 - Genome and proteomic principles in relation to disease and drug development
 - Genetic basis for individualizing drug doses
- PGx contact hours (estimate)
 - 6-8 in required coursework
 - 11/30 required courses report *some* PGx-associated content taught
 - Occurs in lectures + selected recitations

PGx in Required Didactic Courses at UIC

Year	Course Name	Content
P1	PHAR400	Clinical PK
P1	PHAR401	Renal, endocrine
P1	PHAR321	Drug Delivery I
P1	PHAR332	Fundamentals of Drug Action II
P2	PHAR402	Cardiology/ Autonomic
P2	PHAR323	Drug Delivery III
P2	PHAR324	Contemporary Pharm Practice
P2	PHAR403	Infectious Disease
P3	PHAR405	Neurology
P3	PHAR406	Psych/pain
P3	PHAR408	Heme/Onc/ rheumatology

PGx Elective Experiences at UIC

Year	Course Name	Content
Misc (PharmD or PhD)	BPS555	Principles of Pharmacogenomics
Misc (PharmD or PhD)	PMMP412	Pharmaceutical Applications of Genomics and Bioinformatics
Misc (PharmD)	PHAR380/390	Psychiatric Pharmacogenomics (independent study)
Misc (PharmD)	PHAR380/390	Cardiovascular Pharmacogenomics (independent study)
Misc (undergraduate honors)	HONORS/BIOS399	Introduction to Laboratory Psychiatric Pharmacogenomics
P4	PHAR388	Advanced Specialty Clerkship (Psych PGx/Cardio PGx)

Integration Example 1

- PHAR400 – P1 year – Pharmacokinetics
 - 1 x 50 min lecture – “Optimizing Pharmacotherapy with Pharmacogenetics”
 - What is PGx?, PGx nomenclature, intro to genetic variability, warfarin and TPMT clinical examples with cases, genetic variability in drug metabolism across race/ethnic groups, PGx labeling for currently approved agents
 - 2 x 50 min lectures – Sources of PK Variability I&II
 - Additional discussion and cases that include PGx variability in drug metabolism

Integration Example 2

- PHAR402 – P2 year – Cardiology
 - Warfarin PGx
 - Included in antithrombosis section
 - Discussion and case study of using VKORC1/CYP2C9 genotypes + race + weight + etc to select dosing
 - Done alongside “traditional” dosing titration and monitoring recommendations
 - “Bridge” between traditional dosing and dosing guidelines recently incorporated into PI

Integration Example 3

- PHAR406 – P3 year – Psychiatry
 - Carbamazepine PGx
 - Included in Mood Stabilizers II lecture
 - Description of HLA-B*1502 allele
 - Review of racial diversity (more common in SE Asians)
 - Review of testing recommendations
 - Recitation – case study
 - To test or not to test
 - Review of informed consent for genetic testing and how to “counsel” on the test form and potential results

Integration Example 4

- PHAR408 – P3 year – Heme/Onc/Rheumatology
 - Various lectures
 - PGx included as ancillary information – not generally specifically tested
 - Challenge
 - Course material challenging
 - Incorporating PGx details above and beyond general concepts may have diminishing returns

Example 4 Cont'd

- Hematology /Oncology Examples:
 - Trastuzumab – HER2+ status
 - Chronic myleogenous leukemia – BCR-ABL translocation
 - 6-MP - Thiopurinemethyltransferase (*TPMT*)
 - Cetuxumab, panitumumab, erlotinib – EGFR/KRAS status

Applied Elective Experiences

- UIC Pharmacogenomics Lab
 - Undergraduate honors
 - E.g. targeting guaranteed admission students
 - PHAR380/390 Independent Study/Research
 - Advanced Specialty Clerkships
 - Summer PharmD Fellowship Experience
 - ~2 independent study students/semester
 - ~6 rotation students/year
 - ~1-2 summer PharmD student fellows

Applied Elective Experiences: Consistency with flexibility

- All students
 - Lab skills
 - Lab safety, lab etiquette, pipetting, principles of PCR, gel electrophoresis, DNA extraction/quantification/banking, genotyping (Pyrosequencing/TaqMan techniques), etc.
 - Introduction to PGx
 - PGx Tutorials, one-on-one discussion, journal club
 - Paper (lab-report, manuscript style, or review article format)

Applied Elective Experiences: Consistency with flexibility

- Some students
 - Clinical Research
 - HIPAA training, informed consent
 - Subject enrollment
 - Data collection/entry
- Summer Fellows
 - Complete lab based research project, analyze data, write research manuscript

PharmD/PhD Didactic Electives

- BPS555 – Principles of Pharmacogenomics
 - 2 Credit Hours – lecture format
 - Team taught – mix of Biopharmaceutical Sciences and Pharmacy Practice faculty
 - Progression from more “molecular/basic science” to clinical applications
 - In class exam, term paper, 20 min oral presentation

PharmD/PhD Didactic Electives


- BPS555 Cont'd – Principles of Pharmacogenomics
 - Objectives
 - Introduce genetic concepts
 - Explain the molecular basis for genetic variability in humans
 - Identify methods to determine genetic variability
 - Identify clinical applications of PGx
 - Demonstrate the power and challenge of applying PGx in new drug research and development
 - Develop skills to be able to understand, evaluate and design PGx studies
 - Identify potential ethical issues relating to PGx

Challenges

- Incorporating new and innovative technologies to an already packed PharmD curriculum
- Difficult to quantify PGx integration
 - Some “stand alone” lectures needed for foundation
 - Genetic variability treated like another “monitoring” parameter or marker of response
- Integration into therapeutics courses dependent on expertise and/or interest of faculty
- Applied experiences dependent on lab-based faculty with resources and existing/on-going

Opportunities for Growth

- Ethical issues
 - Informed consent issues surrounding testing
 - Patient counseling
 - Implications of genetic testing for self, family, employment, insurance, etc.
- Standardization of integration
- “Real life” application
 - Will increase as more drugs have PGx labeling requirements



University of Connecticut

Pharmacogenomics Education

Megan J. Ehret, PharmD, BCPP

Integrated Curriculum- Pharmacogenomics

- Didactic Coursework in P1, P2, and P3
 - 11-30 hours
 - Multiple faculty involved
- APPE Rotation

The Basics of Genomics

- Cell Biology
 - DNA Structure and Replication
 - Consequences of drugs and mitochondrial genome replication
 - DNA biotechnology
 - Consequences of SNPs for drug metabolism
 - Response vs. nonresponse
 - Gene Regulation

Clinical Pharmacokinetics

- Kinetics vs. Dynamics
- CYP450 Metabolism
 - Ultrarapid, Extensive, Intermediate, Poor
- Pgp
- N-Acetyltransferase type 2
- UGT1A1
- TPMT
- Risk vs. Benefits

Therapeutics

- | | |
|--------------------------------------|-----------------------|
| ■ Nutrition | ■ Psychiatry |
| ■ Autonomic and
Neurologic System | ■ Cardiac |
| ■ Immunology | ■ Renal |
| ■ Dermatology | ■ Respiratory |
| ■ Endocrine | ■ Infectious Disease |
| ■ Gastro-Intestinal | ■ Hematology-Oncology |

Ethics

- Ethical, legal, and social issues related to genomic testing
- Storage of genetic information
- Public policy issues- regulatory statements

Uncovered Areas

- Informed consent process for pharmacogenomic testing
- Specific methods of genotyping and phenotyping
- Important issues in pharmacogenomic study design
- Regulatory issues that may result from testing being incorporated into Phase II and II testing

APPE Rotation

- Psychiatry Rotation
 - Ongoing research studies involving CYP450 enzyme genotyping
 - Ordering labs
 - Interpreting results
 - Discussing results with treatment team and patients

Integrated Pharmacogenomics Vs. One Course

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none">■ Pros<ul style="list-style-type: none">■ Discussion throughout the curriculum■ Each faculty discusses the use/need in their area of expertise■ Frequent assessment of students | <ul style="list-style-type: none">■ Cons<ul style="list-style-type: none">■ Time in each course■ Faculty may not be familiar with the use of pharmacogenomics■ Consistency of terminology and interpretation of results |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|